Wuxi Biologics (Cayman) (2269) Price & Analysis

Compare

44 Followers

2269 Stock Chart & Stats

Day’s Range― - ―

52-Week RangeHK$10.14 - HK$35.60

Previous CloseN/A

Volume35.71M

Average Volume (3M)51.26M

Market Cap

$127.57B

Enterprise ValueHK$71.56B

Total Cash (Recent Filing)$10.71B

Total Debt (Recent Filing)$4.94B

Price to Earnings (P/E)35.4

Beta1.74

Next Earnings

Aug 19, 2025

EPS Estimate

0.49

Last Dividend Ex-Date

Nov 02, 2023

Dividend YieldN/A

Share Statistics

EPS (TTM)0.25

Shares Outstanding4,069,133,500

10 Day Avg. Volume72,451,990

30 Day Avg. Volume51,257,304

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market Cap0.56

Enterprise Value/Revenue3.83

Enterprise Value/Gross Profit9.35

Enterprise Value/Ebitda11.13

Forecast

1Y Price Target

$28.57

Price Target Upside-8.48% Downside

Rating ConsensusModerate Buy

Number of Analyst Covering3

Bulls Say, Bears Say

Bulls Say

Financial PerformanceWuXi Biologics reported impressive results with a 9.6% increase in revenue and a 9.0% rise in adjusted net profit, indicating strong company performance.

Market PositionWuXi Biologics is a leading biologics R&D and manufacturing service provider with a 13% global market share, and is expanding its services overseas.

Revenue GrowthRevenue growth is projected to accelerate in 2025, driven by strong demand and an increase in revenue from continuing operations.

Bears Say

Long-term RisksThe Biosecure Act poses a long-term risk to more than 50% of WuXi Biologics' business in the US.

Market SentimentThe bill has triggered negative market sentiment on Chinese CXOs, with the share prices of all Chinese CXOs correcting even for those companies without cell and gene therapy exposure.

Regulatory RisksThe proposed US Biosecure Act poses regulatory headwinds, potentially banning US companies from dealing with WuXi Biologics, affecting more than 50% of the company's business.

Wuxi Biologics (Cayman) News

WuXi Biologics Reports Robust Financial Growth for H1 2025

An update from Wuxi Biologics (Cayman) ( ($HK:2269) ) is now available. WuXi Biologics has announced a significant...

13d ago

WuXi Biologics Schedules Board Meeting to Review Interim Results

Wuxi Biologics (Cayman) ( ($HK:2269) ) has provided an announcement. WuXi Biologics (Cayman) Inc. has announced a board...

13d ago

WuXi Biologics Announces Share Placement by Substantial Shareholder

Wuxi Biologics (Cayman) ( ($HK:2269) ) has shared an announcement. WuXi Biologics (Cayman) Inc. announced that its substantial...

2M ago

WuXi Biologics Announces AGM Results and Board Changes

Wuxi Biologics (Cayman) ( ($HK:2269) ) has shared an announcement. WuXi Biologics (Cayman) Inc. announced the results of...

2M ago

WuXi Biologics Announces Board Composition and Roles

The latest announcement is out from Wuxi Biologics (Cayman) ( ($HK:2269) ). WuXi Biologics (Cayman) Inc. has announced...

2M ago

Wuxi Biologics Grants Restricted Shares to Motivate Employee

An announcement from Wuxi Biologics (Cayman) ( ($HK:2269) ) is now available. Wuxi Biologics has announced the grant...

2M ago

Wuxi Biologics Announces 2025 Annual General Meeting Agenda

The latest announcement is out from Wuxi Biologics (Cayman) ( ($HK:2269) ). Wuxi Biologics (Cayman) Inc. announced its...

3M ago

WuXi Biologics Announces Hong Kong Address Change and Completes Vaccine Facility Transaction

Wuxi Biologics (Cayman) ( ($HK:2269) ) has issued an announcement. WuXi Biologics (Cayman) Inc. has announced a change...

4M ago

WuXi Biologics: Strong Growth and Strategic Expansion Drive Buy Rating and Target Price Increase

Analyst Jill Wu of CMB International Securities maintained a Buy rating on Wuxi Biologics (Cayman) (WXIBF – Research...

4M ago

Wuxi Biologics Grants Over 25 Million Restricted Shares to Employees

Wuxi Biologics (Cayman) ( ($HK:2269) ) has issued an update. Wuxi Biologics has announced the approval of a...

4M ago

WuXi Biologics downgraded to Neutral from Buy at Goldman Sachs

Goldman Sachs downgraded WuXi Biologics to Neutral from Buy with a price target of HK$21.60, down from HK$50....

1y ago

GSK, WuXi Biologics enter into license agreement on TCE antibodies

WuXi Biologics (WXIBF) announced a license agreement with GSK plc (GSK) under which GSK will have exclusive licenses...

3y ago

GSK

2269 FAQ

What was Wuxi Biologics (Cayman) Inc.’s price range in the past 12 months?

Wuxi Biologics (Cayman) Inc. lowest stock price was HK$10.14 and its highest was HK$35.60 in the past 12 months.

What is Wuxi Biologics (Cayman) Inc.’s market cap?

Wuxi Biologics (Cayman) Inc.’s market cap is $127.57B.

When is Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date?

Wuxi Biologics (Cayman) Inc.’s upcoming earnings report date is Aug 19, 2025 which is in 14 days.

How were Wuxi Biologics (Cayman) Inc.’s earnings last quarter?

Wuxi Biologics (Cayman) Inc. released its earnings results on Mar 25, 2025. The company reported HK$0.246 earnings per share for the quarter, missing the consensus estimate of HK$0.481 by -HK$0.235.

Is Wuxi Biologics (Cayman) Inc. overvalued?

According to Wall Street analysts Wuxi Biologics (Cayman) Inc.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Wuxi Biologics (Cayman) Inc. pay dividends?

Wuxi Biologics (Cayman) Inc. pays a Notavailable dividend of HK$0.055 which represents an annual dividend yield of N/A. See more information on Wuxi Biologics (Cayman) Inc. dividends here

What is Wuxi Biologics (Cayman) Inc.’s EPS estimate?

Wuxi Biologics (Cayman) Inc.’s EPS estimate is 0.49.

How many shares outstanding does Wuxi Biologics (Cayman) Inc. have?

Wuxi Biologics (Cayman) Inc. has 4,069,133,500 shares outstanding.

What happened to Wuxi Biologics (Cayman) Inc.’s price movement after its last earnings report?

Wuxi Biologics (Cayman) Inc. reported an EPS of HK$0.246 in its last earnings report, missing expectations of HK$0.481. Following the earnings report the stock price went down -1.708%.

Which hedge fund is a major shareholder of Wuxi Biologics (Cayman) Inc.?

Currently, no hedge funds are holding shares in HK:2269

Wuxi Biologics (Cayman) Stock Smart Score

Outperform

Fundamentals

Return on Equity

8.17%

Trailing 12-Months

Asset Growth

-2.15%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Wuxi Biologics (Cayman) Inc.

Wuxi Biologics (Cayman) Inc. is a leading global open-access biologics technology platform company, providing end-to-end solutions for biologics discovery, development, and manufacturing. Headquartered in Wuxi, China, the company operates in the biotechnology and pharmaceutical sectors, offering a comprehensive range of services to its clients, including monoclonal antibodies, bispecific antibodies, fusion proteins, and other biologics. Wuxi Biologics caters to a diverse clientele, including multinational pharmaceutical companies, biotechnology companies, and research institutions worldwide.

Wuxi Biologics (Cayman) (2269) Earnings & Revenues

HK:2269 Earnings Data >

2269 Company Deck

2269 Earnings Call

Q4 2025

0:00 / 0:00

2269 Stock 12 Month Forecast

Average Price Target

HK$28.57

▼(-8.48%Downside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"9":"HK$9","22":"HK$22","35":"HK$35","15.5":"HK$15.5","28.5":"HK$28.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":34.230000019887974,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$34.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":28.5734471204,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$28.57</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":23.400000013595633,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$23.40</span>\n  </div></div>","useHTML":true}}],"tickPositions":[9,15.5,22,28.5,35],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2024","6":"Nov<br/>2024","9":"Feb<br/>2025","12":"Jul<br/>2025","25":"Jul<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.65,26.310000001529843,26.97000000305969,27.630000004589533,28.290000006119374,28.95000000764922,29.610000009179064,30.27000001070891,30.930000012238754,31.590000013768595,32.25000001529844,32.910000016828285,33.57000001835813,{"y":34.230000019887974,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.65,25.874880547723077,26.09976109544615,26.32464164316923,26.549522190892308,26.774402738615386,26.99928328633846,27.22416383406154,27.449044381784617,27.67392492950769,27.89880547723077,28.123686024953848,28.348566572676923,{"y":28.5734471204,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,25.65,25.476923077968895,25.303846155937787,25.130769233906683,24.95769231187558,24.784615389844472,24.611538467813368,24.438461545782264,24.26538462375116,24.092307701720053,23.91923077968895,23.746153857657845,23.573076935626737,{"y":23.400000013595633,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":13.74,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.14,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.18,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.42,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.88,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.5,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.32,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":15.5,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.56,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.48,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.45,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.8,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":25.65,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >